The at-home treatment could assist people who are unable to travel to immunization appointments. | Photo by Jeff Gritchen/Digital First Media/Orange County Register via Getty Images The Food and Drug Administration has approved a nasally-administered influenza immunization treatment that can be taken at home. FluMist — a nasal spray vaccine that AstraZeneca initially developed as an in-office treatment two decades ago — will still require a prescription to obtain and is expected to be made available via a new online pharmacy next year, according to The New York Times. The treatment will require people to fill out a questionnaire on the upcoming FlueMist Home website. Once approved by a pharmacist, the nasal spray will be shipped directly to the customer’s door. The current out-of-pocket cost is around $35 to $45 per dose according to the NYT, but that may drop depending on insurance coverage. The Centers for Disease... Continue reading…